79 related articles for article (PubMed ID: 22902456)
1. [A case of colon cancer with chronic renal dysfunction responding to effective retreatment with FOLFIRI].
Kitade H; Shimasaki T; Yoshimitsu Y; Okuda M; Hokkoku K; Mori M; Shintaku K; Sakuma H; Ueda H; Nakai M
Gan To Kagaku Ryoho; 2012 Aug; 39(8):1267-70. PubMed ID: 22902456
[TBL] [Abstract][Full Text] [Related]
2. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
Van Cutsem E; Köhne CH; Láng I; Folprecht G; Nowacki MP; Cascinu S; Shchepotin I; Maurel J; Cunningham D; Tejpar S; Schlichting M; Zubel A; Celik I; Rougier P; Ciardiello F
J Clin Oncol; 2011 May; 29(15):2011-9. PubMed ID: 21502544
[TBL] [Abstract][Full Text] [Related]
3. [A case of undifferentiated colon cancer responding to FOLFIRI therapy].
Fujiwara K; Nagayoshi Y; Nakahara C; Yamasaki T; Iwashita T
Gan To Kagaku Ryoho; 2011 Sep; 38(9):1525-7. PubMed ID: 21918355
[TBL] [Abstract][Full Text] [Related]
4. [A case of colon cancer with multiple lung metastases responding completely to FOLFIRI and FOLFOX therapy].
Kume S; Takahashi M; Kubota T; Hirata T; Torigoe Y; Ikeda O; Goto Y
Gan To Kagaku Ryoho; 2010 Sep; 37(9):1809-12. PubMed ID: 20841953
[TBL] [Abstract][Full Text] [Related]
5. [A case of locally advanced sigmoid colon cancer curatively resected after neoadjuvant chemotherapy with FOLFIRI plus panitumumab].
Horioka K; Kaku K; Jimi S; Oohata Y; Kamei T
Gan To Kagaku Ryoho; 2013 Mar; 40(3):397-9. PubMed ID: 23507607
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
[TBL] [Abstract][Full Text] [Related]
7. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
[TBL] [Abstract][Full Text] [Related]
8. [A case of colon cancer with multiple liver metastases responding ot S-1 as third-line treatment following FOLFIRI and FOLFOX].
Miyahira T; Teruya N; Matsuura F; Murayama S; Aka H; Teruya J; Hanashiro N; Nishihara M; Okushima N; Toda Y; Kiyuna M
Gan To Kagaku Ryoho; 2010 Feb; 37(2):331-4. PubMed ID: 20210032
[TBL] [Abstract][Full Text] [Related]
9. [Third-line therapy in a patient with recurrent colon cancer undergoing hemodialysis].
Matsuda M; Seyama Y; Inada K; Miyata Y; Shida D; Maeshiro T; Miyamoto S; Umekita N
Gan To Kagaku Ryoho; 2013 Oct; 40(10):1397-400. PubMed ID: 24196079
[TBL] [Abstract][Full Text] [Related]
10. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.
Van Cutsem E; Lenz HJ; Köhne CH; Heinemann V; Tejpar S; Melezínek I; Beier F; Stroh C; Rougier P; van Krieken JH; Ciardiello F
J Clin Oncol; 2015 Mar; 33(7):692-700. PubMed ID: 25605843
[TBL] [Abstract][Full Text] [Related]
11. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Taieb J; Tabernero J; Mini E; Subtil F; Folprecht G; Van Laethem JL; Thaler J; Bridgewater J; Petersen LN; Blons H; Collette L; Van Cutsem E; Rougier P; Salazar R; Bedenne L; Emile JF; Laurent-Puig P; Lepage C;
Lancet Oncol; 2014 Jul; 15(8):862-73. PubMed ID: 24928083
[TBL] [Abstract][Full Text] [Related]
12. An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.
Cohn AL; Shumaker GC; Khandelwal P; Smith DA; Neubauer MA; Mehta N; Richards D; Watkins DL; Zhang K; Yassine MR
Clin Colorectal Cancer; 2011 Sep; 10(3):171-7. PubMed ID: 21855038
[TBL] [Abstract][Full Text] [Related]
13. Prospective analysis of KRAS wild-type patients with metastatic colorectal cancer using cetuximab plus FOLFIRI or FOLFOX4 treatment regimens.
Huang MY; Chen MJ; Tsai HL; Kuo CH; Ma CJ; Hou MF; Chuang SC; Lin SR; Wang JY
Genet Mol Res; 2011 Oct; 10(4):3002-12. PubMed ID: 21968808
[TBL] [Abstract][Full Text] [Related]
14. KRAS status predicts response to cetuximab for metastatic colorectal cancer.
McBride D
ONS Connect; 2008 Aug; 23(8):25. PubMed ID: 18767573
[No Abstract] [Full Text] [Related]
15. [mFOLFOX6 and FOLFIRI/bevacizumab treatment in a patient on hemodialysis with metastatic colon cancer].
Kuwabara H; Baba H; Wakabayashi M; Nakamura H; Sanada T; Baba H; Nakajima K; Goseki N
Gan To Kagaku Ryoho; 2011 Nov; 38(12):2250-2. PubMed ID: 22202345
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status.
Mitchell EP; Piperdi B; Lacouture ME; Shearer H; Iannotti N; Pillai MV; Xu F; Yassine M
Clin Colorectal Cancer; 2011 Dec; 10(4):333-9. PubMed ID: 22000810
[TBL] [Abstract][Full Text] [Related]
17. [A case of unresectable multiple hepatic metastases from ascending colon cancer successfully treated with panitumumab and FOLFIRI(5-FU/LV/irinotecan)therapy].
Yoshida R; Matsuura T; Hijikawa K; Yanagida H; Kitade H; Takada H; Kwon AH
Gan To Kagaku Ryoho; 2012 Oct; 39(10):1575-7. PubMed ID: 23064076
[TBL] [Abstract][Full Text] [Related]
18. The combination of 5-FU, leucovorin and CPT-11 (FOLFIRI) prolongs survival through inhibition of metastasis in an orthotopic model of colon cancer.
Ishihara Y; Matsunaga K; Iijima H; Hasegawa G; Suzuki T; Sato A; Kobayashi T; Yang M; Hoffman RM
Anticancer Res; 2010 Feb; 30(2):403-8. PubMed ID: 20332446
[TBL] [Abstract][Full Text] [Related]
19. Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin.
Láng I; Köhne CH; Folprecht G; Rougier P; Curran D; Hitre E; Sartorius U; Griebsch I; Van Cutsem E
Eur J Cancer; 2013 Jan; 49(2):439-48. PubMed ID: 23116683
[TBL] [Abstract][Full Text] [Related]
20. [Long-Term Successful Management of Recurrent Rectal Cancer in the Predialysis State with FOLFIRI Chemotherapy].
Koike N; Takeuchi T; Fujii T; Ohshima Y; Arita S; Isaka N; Shinozaki E
Gan To Kagaku Ryoho; 2015 Nov; 42(11):1427-30. PubMed ID: 26602405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
